SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral RegimenSWIFT: 항레트로바이러스 요법을 포함하는 강화된 프로테아제 억제제를 사용하는 바이러스학적으로 억제된 HIV-1 감염 환자에서 라미부딘/아바카비르에서 엠트리시타빈/테노포비어로 전환하는 것의 효능 및 안전성을 평가하기 위한 전향적 48주 연구HIV/AIDS Published on 2013-06-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] 3TC/ABC 95% confidence interval abacavir addition Arm ARMS backbone baseline characteristics calculated CD4 Characteristics cholesterol compared Containing Decline decrease Decreased defined Efficacy and safety EGFR emtricitabine emtricitabine/tenofovir epidermal epidermal growth factor evaluate FTC/TDF fumarate GFR greater growth factor HIV patient HIV patients HIV-1 Human immunodeficiency virus immunodeficiency virus improvement Improvements Infected inhibitor lamivudine LDL Lipid lipids Lipoproteins Low-density lipoprotein low-density lipoproteins male median median age nucleoside Open-label parameter Patient PI primary endpoint Prospective Protease inhibitor Randomized rebound receiving receptor regimen reverse transcriptase risk score Ritonavir RNA RTV Safety study drug subject suppressed switch switching tenofovir disoproxil fumarate TG The United States threshold Total cholesterol transcriptase treated treatment difference Triglyceride triglycerides United States virologic failure Virologic suppression [DOI] 10.1093/cid/cis1203 PMC 바로가기 [Article Type] HIV/AIDS